Biopharma | May 24, 2025
Sun Pharma to raise stake in US-based Pharmazz to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Subscribe To Our Newsletter & Stay Updated
